Drug intelligence / Profile preview

Protexi

Development stage: Preclinical
Lead developer: Celloram
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

Protexi is a therapeutic vaccine initially developed by Celloram. Its primary indication is for the treatment of neoplasms, specifically sarcoma. As of March 2025, its highest development status is preclinical. The detailed mechanism of action, molecular targets, and composition have not been disclosed in public sources. There are no approved uses or clinical trial results available for this product as of the latest update[5].

Brand names: Protexi

Beyond the preview

Go deeper on Protexi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protexi.

Explore the full profile